PSA前列腺治疗变形价值水ADT摘要:doi:10.4103/aja.aja_24_18Yasutaka YamadaDepartment of UrologyHiroomi NakatsuDepartment of UrologyShinichi SakamotoDepartment of UrologyYoshiyasu AmiyaDepartment of UrologyMakoto SasakiDepartment of UrologyTakayuki ShimaDepartment of UrologyAkira KomiyaDepartment of UrologyNoriyuki ...
Among men with elevated prostate-specific antigen (PSA) but no CaP, the mortality rates were slightly lower, and fewer differences in comorbidities and medication use were noted compared to men without elevated PSA. Many prevalent comorbidities and medications were consistent across groups and are ...
These findings suggest that high serum levels of CEA and CA19-9 in patients with prostate cancer are indications of hormone-refractory prostate cancer ... Y Kinebuchi,W Noguchi,K Irie,... 被引量: 0发表: 2007年 High Stage Prostate Cancer with Low Serum PSA Level: A Case Report Serum pro...
B, Decision curve analysis plots illustrating the net reduction in biopsies performed per 100 patients without missing a single diagnosis of cancer of grade group 2 or greater based on prebiopsy testing with PSA alone, the Prostate Cancer Prevention Trial risk calculator, PHI, the derived multiplex...
Re-biopsy with preceded MRI yields higher cancer detection rate and positive core rate than re-biopsy without preceded MRI. MRI should be considered prior to re-biopsy in patients with previous negative biopsy and persistently high PSA. This is a preview of subscription content, log in via an ...
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 The threat of prostate cancer and the significant and often negative impact of its treatment underscore the importance of prevention. High-grade prostatic ... JR Marshall,CM...
Objective High-dose-rate (HDR) brachytherapy boost represents a method to dose escalate in high-risk prostate cancer; the purpose of this analysis is to report long-term outcomes for a group of high-risk patients with Gleason 8 through 10 prostate cancer treated with HDR brachytherapy boost from...
Diagnostic and therapeutic decisions are commonly driven by anomalous levels of PSA in patients’ blood while, on the other hand, this antigen is known to be prostate-specific but not cancer-specific8. The standard screening threshold of 4.1 ng/mL has recently been challenged and accurate cut...
External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Purpose: To characterize the relationship of radiotherapy dose to prostate cancer patient outcome, with an emphasis on the influence of pretreatment progno... A Pollack,LG Smith,ACV Eschenb...
Patients with high-risk prostate cancer treated with curative intent are at an increased risk of biochemical recurrence, metastatic progression and cancer-related death compared with patients treated for low-risk or intermediate-risk disease. Thus, these